Procedure Slowdown, DoJ Probe Lowers Performance Outlook For AtriCure
This article was originally published in The Gray Sheet
Executive Summary
A recent slowdown in procedure volumes, attributed to the troubled economy, and a Department of Justice investigation into marketing practices have cardiac ablation system maker AtriCure reassessing its expectations for near-term growth
You may also be interested in...
J&J Gets Panel Date Seeking First A-Fib Ablation Catheter Indication
Johnson & Johnson's chances of becoming the first firm to market an ablation device in the U.S. labeled for treating atrial fibrillation will be clearer next month, when the company is scheduled to present PMA supplement data to an FDA advisory panel
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.